Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals held an Extraordinary General Meeting where shareholders approved several resolutions, including the ratification of prior issues and approvals for future issues of convertible notes and options. These decisions are expected to support the company’s financial strategy and enhance its capacity to advance its drug development initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focusing on improving patients’ health through pharmaceutical therapies. The company is currently developing iPPS for treating diseases with significant inflammation, such as osteoarthritis.
Average Trading Volume: 869,046
Technical Sentiment Signal: Sell
Current Market Cap: A$121.5M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.